Safety and immunogenicity of SpiN-Tec, a T-cell based RBD-Nucleocapsid chimeric vaccine for COVID-19
Authors:
Open Access
Abstract
No abstract availableKeywords
Funding Information
- Fundação de Amparo à Pesquisa do Estado de São Paulo (2020/05527\u20130 R.T.G.)
- Ministério da Ciência, Tecnologia, Inovações e Comunicações (01.20.0005.00)
- Ministério da Ciência, Tecnologia, Inovações e Comunicações (01.20.0010)
- CNPq (403701/2020\u20131 R.T.G.)
- CNPq (403514/2020\u20137)
- Ministério da Educação
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
- Inova Health System
- Fundação Oswaldo Cruz
This publication has 15 references indexed in Scilit:
- SpiN-Tec: A T cell-based recombinant vaccine that is safe, immunogenic, and shows high efficacy in experimental models challenged with SARS-CoV-2 variants of concernVaccine, 2024
- Evaluation of an RBD-nucleocapsid fusion protein as a booster candidate for COVID-19 vaccineiScience, 2024
- Nucleocapsid-specific T cell responses associate with control of SARS-CoV-2 in the upper airways before seroconversionNature Communications, 2023
- SARS-CoV-2 variant biology: immune escape, transmission and fitnessNature Reviews Microbiology, 2023
- Promotion of neutralizing antibody-independent immunity to wild-type and SARS-CoV-2 variants of concern using an RBD-Nucleocapsid fusion proteinNature Communications, 2022
- The SARS-CoV-2 mutations versus vaccine effectiveness: New opportunities to new challengesJournal of Infection and Public Health, 2022
- Adaptive immunity to SARS-CoV-2 and COVID-19Cell, 2021
- Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trialThe Lancet Infectious Diseases, 2021
- What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2The Lancet Infectious Diseases, 2021
- Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed IndividualsCell, 2020